If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-18. Numbers and descriptions here follow the published literature rather than marketing material.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
== Awards and honours == Robinson has received many honors working as a cellular biologist. She was awarded a Wellcome Trust Principal Research Fellowship in 1999 and in 2003 she was appointed Professor of Molecular Cell Biology. She was elected a Fellow of the Academy of Medical Sciences in 2001 and member of the European Molecular Biology Organization in the same year. She was elected a Fellow of the Royal Society (FRS) in 2012. The Wellcome Trust also has funded her research for over 25 years.
Banting House is a museum and former residence in London, Ontario, Canada. Known as the “Birthplace of Insulin,” it is the house where Sir Frederick Banting woke up at two o'clock in the morning on October 31, 1920 with the idea that led to the discovery of insulin. Since 1984, the house has been a museum dedicated to Banting's discovery and his life. An addition at the back houses the London & District Branch of the Canadian Diabetes Association. For many that have been touched by diabetes, the house is an emotional reminder of Banting's scientific contribution that saved their lives or the lives of their loved ones.
=== Other and unspecified disorders of metabolism === 277 Other and unspecified disorders of metabolism 277.0 Cystic fibrosis 277.1 Disorders of porphyrin metabolism Porphyria Acute intermittent porphyria 277.2 Other disorders of purine and pyrimidine metabolism Lesch–Nyhan syndrome Purine nucleoside phosphorylase deficiency Xanthinuria 277.3 Amyloidosis Familial Mediterranean fever 277.4 Hyperbilirubinemia Crigler–Najjar syndrome Gilbert's syndrome 277.5 Mucopolysaccharidosis Hunter syndrome Hurler syndrome Morquio–Brailsford disease Sanfilippo syndrome 277.6 Other deficiencies of circulating enzymes Alpha 1-antitrypsin deficiency Biotinidase deficiency Hereditary angioedema 277.7 Dysmetabolic syndrome X Metabolic syndrome 277.8 Other specified disorders of metabolism 277.81 Primary carnitine deficiency 277.82 Carnitine deficiency due to inborn errors of metabolism 277.83 Iatrogenic carnitine deficiency 277.84 Other secondary carnitine deficiency 277.85 Disorders of fatty acid oxidation metabolism Carnitine palmitoyltransferase I deficiency Carnitine palmitoyltransferase II deficiency Very long-chain acyl-coenzyme A dehydrogenase deficiency Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency Medium-chain acyl-coenzyme A dehydrogenase deficiency 277.86 Disorders of peroxisomal metabolism Zellweger syndrome 277.87 Disorders of mitochondrial metabolism Kearns–Sayre syndrome Mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS syndrome) Mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE) Myoclonus with epilepsy and with ragged red fibers (MERRF syndrome) Neuropathy, ataxia, and retinitis pigmentosa (NARP syndrome) 277.88 Tumor lysis syndrome 277.89 Other specified disorders of metabolism
Sources: en.wikipedia.org
karyogram A karyotype which depicts the entire set of chromosomes in a cell or organism by using photomicrographs of the actual chromosomes as they appear in vivo (usually during metaphase, in their most condensed forms), as opposed to the idealized illustrations of chromosomes used in idiograms. The photomicrographs are often still arranged in pairs and by size for easier identification of particular chromosomes, whereas in the actual nucleus there is seldom any apparent organization.
However, in low-confidence regions, the RMSD can exceed 2 Å, indicating greater deviations. In proteins with multiple domains connected by flexible linkers, AlphaFold2 predicts individual domain structures accurately but may assign random relative positions to these domains. Additionally, AlphaFold2 does not account for structural constraints such as the membrane plane, sometimes placing protein domains in positions that would physically clash with the membrane.
== References == Sutera, S. P.; Skalak, R. (1993). "The history of Poiseuille's law". Annual Review of Fluid Mechanics. 25: 1–19. Bibcode:1993AnRFM..25....1S. doi:10.1146/annurev.fl.25.010193.000245.. Pfitzner, J (1976). "Poiseuille and his law". Anaesthesia. Vol. 31, no. 2 (published Mar 1976). pp. 273–5. doi:10.1111/j.1365-2044.1976.tb11804.x. PMID 779509.. Bennett, C. O.; Myers, J. E. (1962). Momentum, Heat, and Mass Transfer. McGraw-Hill..
Sources: en.wikipedia.org
He pleaded no contest on November 25, and was given a year's probation, a $1,000 fine, and ordered to carry out 80 hours of community service. In 2007, Marshall told Fox News that WWE knew of the abuse, but worked to keep her from revealing that Austin had hit her as it would cost the company millions of dollars. Austin responded to the incident in 2003 through WWE Raw Magazine, citing his regret over their relationship breaking down and stating his love for Marshall. He also ridiculed allegations that the incident was alcohol-related. He filed for divorce from Marshall on July 22, 2002, which was finalized on February 5, 2003. In March 2003, during the hours leading up to WrestleMania XIX, Austin was rushed to the hospital for twitchiness and a high heart rate. In 2003, Austin denied allegations that he was an alcoholic, stating that wrestling fans had mistaken his character's excessive consumption of beer as a real-life trait of his and insisting that he drinks responsibly. In March 2004, he was accused of assaulting his then-girlfriend Tess Broussard during a dispute at his home in San Antonio, Texas, according to a police report. No arrests were made and no charges were filed in the case. In 2007, the Wrestling Observer newsletter reported that Austin had legally changed his name to Steve Austin. In late 2009, Austin married his fourth wife, Kristin Feres. In 2014, Austin voiced support for same-sex marriage on his podcast. Also in 2014, Austin released his first beer, Broken Skull IPA, with El Segundo Brewing Company in California.
Three of the four outer-shell electrons of each atom in a graphene sheet occupy three sp2 hybrid orbitals – a combination of orbitals s, px and py — that are shared with the three nearest atoms, forming σ-bonds. The length of these bonds is about 0.142 nanometers. The remaining outer-shell electron occupies a pz orbital that is oriented perpendicularly to the plane. These orbitals hybridize together to form two half-filled bands of free-moving electrons, π, and π∗, which are responsible for most of graphene's notable electronic properties. Recent quantitative estimates of aromatic stabilization and limiting size derived from the enthalpies of hydrogenation (ΔHhydro) agree well with the literature reports. Graphene sheets stack to form graphite with an interplanar spacing of 0.335 nm (3.35 Å). Graphene sheets in solid form usually show evidence in diffraction for graphite's (002) layering. This is true of some single-walled nanostructures. However, unlayered graphene displaying only (hk0) rings have been observed in the core of presolar graphite onions. TEM studies show faceting at defects in flat graphene sheets and suggest a role for two-dimensional crystallization from a melt.
Autoimmune disorder, such as systemic lupus erythematosus (SLE), rheumatoid arthritis, and Sjögren's syndrome Chronic liver disease, such as cirrhosis Certain medications, including thiazide diuretics and opiates Genetic factors: There may be a genetic component
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.